| Global API The size of the market in 2006, about | | | | 67%. |
| 33.6 billion U.S. dollars. The market has been a hotbed | | | | In China, the factory put into operation with a large |
| of outsourcing, more than half of them being | | | | number of Chinese companies and multinational |
| outsourced to India, China and other low-cost Asian | | | | companies have enjoyed the advantage of low labor |
| countries. This outsourcing trend has been in the past | | | | costs have faded now. This has prompted more and |
| few years to fully develop. With the large | | | | more Chinese companies focus on improving |
| pharmaceutical companies significant increase in | | | | production processes. |
| demand, outsourcing gradually from a tactical or | | | | Compared with India, in volume production for |
| opportunistic only choice, evolved into the | | | | bio-pharmaceutical products, bulk drugs in the field, |
| maintenance business to develop and maintain an | | | | the Chinese company has not established a solid |
| industry leading strategic choice, which in turn | | | | foundation, this area could barely see the figures of |
| contracts in India and China service providers have an | | | | Chinese companies. So far, the Chinese |
| enormous opportunity. | | | | pharmaceutical company (whether private or |
| Present, large pharmaceutical companies are turning | | | | state-owned enterprises) are relatively low innovation |
| to contract manufacturing organizations. Global API | | | | capacity, they have been engaged in the production |
| Market, usually between India and China shows the | | | | and delivery of innovative products, non-traditional |
| trend of competition and cooperation. | | | | medicines. |
| Focus on traditional Chinese medicines Chinese | | | | Help multinational companies in India to develop |
| companies have been on the market for Western | | | | intellectual property protection policies |
| medicines developed expertise in reverse engineering. | | | | The Indian market as the contract manufacturer |
| As a result, China emerged a large number of | | | | provides a great opportunity. India has 1.095 billion |
| experienced staff, they are very understanding of | | | | people, from the local market itself, this is |
| pharmaceutical process engineering. This not only | | | | undoubtedly a great opportunity. |
| provides for the multinational pharmaceutical | | | | India in 2005 after the implementation of the reform |
| companies a talent pool, but also makes the Chinese | | | | the patent system, transnational corporations will |
| company in the design process when the non-patent | | | | outsource production of more and more Indian |
| infringement can be innovative. | | | | companies are assured that this is because India is |
| China's pharmaceutical industry has also established a | | | | now not only have the production skills and |
| number of sizeable infrastructure, such as factories | | | | infrastructure, but also conducive to the development |
| and equipment suppliers. Indeed, while India is outside | | | | of the intellectual property protection policies of |
| the United States by the U.S. Food and Drug | | | | transnational corporations. India with multinational |
| Administration (FDA) approved the largest number of | | | | companies want to use a variety of advantages: |
| state factories, but China has become India's bulk | | | | lower labor costs, meet the standards established by |
| drug market is the preferred equipment supplier is an | | | | the U.S. FDA, specializing in the production of generic |
| indisputable fact. | | | | drugs, as well as in production quality, capacity and |
| Traditionally, Chinese API companies have been | | | | compliance more prominent and so on. |
| locked in the eyes of the field of chemical synthesis, | | | | In India contract research and manufacturing services |
| and are mostly used for domestic Pharmaceutical | | | | (CRAMS) market, the contract manufacturing |
| market . However, after several years of | | | | business accounted for a large proportion. In 2006, |
| development, this situation began to change. At | | | | the business accounted for CRAMS market revenue |
| present, India's bulk drugs production and 60% for | | | | share of about 71%. |
| exports, while China represented approximately 50%. | | | | India's main advantage is its cost, it has been widely |
| Bulk drugs market in Western Europe, India and China | | | | publicized, and has been well received. Compared with |
| share of the company total more than 60%. It is | | | | Western countries, the cost of production in India |
| estimated that by 2010, this proportion will rise to | | | | can save about 60%. |